News

Eli Lilly has announced positive phase II study results of LY2189265, an investigational glucagon-like peptide 1 (GLP-1) analog. It is to be administered subcutaneously once a week for

Somaxon, a specialty pharmaceutical company has announced that it has resubmitted New Drug Application (NDA) to FDA for Silenor (doxepin) for the treatment of insomnia. The resubmission includes

Strativa announced that the FDA has accepted its New Drug Application (NDA) for ondansetron orally dissolving film strip (ODFS) for the prevention of nausea and vomiting associated with

Magellan Health Services has signed a definitive agreement to acquire First Health Services Corporation, a subsidiary of Coventry Health Care, which provides pharmacy benefits administration and other services

Novartis has announced positive results for Tasigna (nilotinib), for treating newly diagnosed chronic myeloid leukemia (CML). The research compared Tasigna against historical Glivec (imatinib) data in the treatment

Merck has announced the results for the pivotal phase-III study of rolofylline (MK-7418), the investigational medicine for the treatment of acute heart failure. The results showed that rolofylline

Proximagen has announced that it has conditionally placed 35714286 new ordinary shares of 1p each at a price of 140 pence per share, to raise gross proceeds of

The World Health Organisation (WHO) has awarded global prequalification to GlaxoSmithKline’s vaccine against rotavirus, Rotarix. As part of an innovative ‘South-first’ access strategy, GSK Biologicals launched Rotarix in

XTENT has announced that it has received conditional approval from FDA for IDE, authorizing it to begin its pivotal clinical program, composed of two trials called Custom IV